Aarti Drugs
Update in progressAARTIDRUGS.NS (NSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Aarti Drugs Limited and its subsidiaries manufacture and market active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations for India and international markets. Their portfolio includes APIs such as diclofenac, ciprofloxacin, levofloxacin, nimesulide, zolpidem, ketoconazole, fluconazole, pioglitazone, metformin, vildagliptin, raloxifene, and tinidazole, plus related intermediates. They develop antifungal, cardiovascular, antidiabetic, and NSAID drugs. Established 1984, Mumbai.
Company score
- Sentiment
- -0.07
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- -0.32
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.06
- Governance
- -0.28
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.18
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.13
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!